Nura Bio is a clinical-stage biopharmaceutical company focused on developing small molecule neuroprotective therapies that halt axon degeneration by inhibiting SARM1. Its lead programs include NB-4746, a first-generation oral, brain-penetrant reversible orthosteric SARM1 inhibitor currently in a Phase 1b/2a global ALS study, and NB-9402, a second-generation oral covalent irreversible allosteric SARM1 inhibitor in a Phase 1a first-in-human study. NB-4746 demonstrated a favorable safety profile and achieved target plasma and cerebrospinal fluid exposure in a Phase 1 study in healthy volunteers, and preclinical studies支持 neuroprotection across central, peripheral, and ocular nervous system models. The company intends to use proceeds from its recently completed $73.8M Series B to fund clinical proof-of-biology studies and advance its clinical pipeline. Nura Bio is based in South San Francisco and is positioning a portfolio of differentiated SARM1 inhibitors to explore therapeutic potential across multiple neurological diseases.

Total raised

$287M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2026